Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
OMC reaches its October 13 Q3 earnings release with short interest climbing back toward the month's highs, a put-heavy options market, and an analyst community that trimmed targets just days before the print.
The most notable shift since the October 10 preview is that short interest has moved higher, not lower. The position rose roughly 7.6% over the past week to 12.7% of free float, reversing the easing trend noted three days ago. That puts shorts back near where they were in mid-September, after briefly pulling back through late September and early October. Days to cover remain 6.3 on the latest FINRA data, meaning a covering event would take real time. The borrow market itself offers no drama: cost to borrow is just 0.51%, up marginally on the week, and availability of around 615% means the lending pool is far from stretched. Shorts have rebuilt their position without any pressure from the borrow side. That is a deliberate stance, not a forced one.
Options positioning reinforces the cautious read, though not at an extreme. The put/call ratio of 1.54 runs slightly above its 20-day average of 1.50, and the trend has been clear since late August: PCR climbed from around 1.04 to its current level as the stock drifted lower over the month. The z-score of 0.47 is modest, placing the reading less than half a standard deviation above recent norms, so options traders are hedged rather than panicked. The ORTEX short score has been drifting higher all week, reaching 59.1 by October 12 from 56.3 a week earlier, consistent with the short interest rebuild.
The Street picture is one of cautious bulls versus a stock that has underperformed. Barclays trimmed its target to $88 from $90 on October 9, maintaining Equal-Weight, right on the eve of the print. The mean analyst target of $102 implies around 32% upside from the current $77.07, but that gap has been widening as the stock fell roughly 2.5% over the past month while targets have come down incrementally. Goldman Sachs initiated at Buy with a $146 target in June, which now looks aggressive relative to the cluster of targets in the $83 to $114 range from Morgan Stanley, Wells Fargo, Citi and UBS. On valuation, the stock trades at a forward P/E of 6.8 and EV/EBITDA of 5.6, both down over 30 days. The 12-month forward EPS growth factor ranks in the 92nd percentile, suggesting the earnings trajectory is the bull case, even if the multiple has drifted. The dividend score of 93 reflects a consistent payer, though the dividend data in the snapshot is stale and cannot be relied upon for current yield.
Institutional ownership is dominated by index and quasi-index holders: BlackRock at 10.4%, State Street at 8.96%, and the Vanguard complex collectively holding well above 10%. No 13D activist is on the register. The most active recent institutional movement came from Hotchkis and Wiley, which added roughly 1.5 million shares through August, and FMR, which added over 1.1 million. Neither of those shifts is recent enough to read as a direct reaction to today's print, but both represent value-oriented buyers accumulating into weakness.
The next thing to watch is how the Q3 numbers interact with a short book that has just rebuilt into the print. A revenue beat that clears the bar on organic growth would pressure covers. A miss, particularly on margins, would validate the put positioning and the short rebuild that has been running all week.
See the live data behind this article on ORTEX.
Open OMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
